References

  1. Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1-12.

  2. Holmes DR Jr, Doshi SK, Kar S, et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol. 2015;65(24):2614-2623.

  3. Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1-12. 

  4. Reddy VY, Sievert H, Halperin J, et al; for the PROTECT AF Steering Committee and Investigators. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014;312(19):1988-1998.

  5. Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1-12.

  6. Reddy VY, Doshi SK, Kar S, et al. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. J. Am Coll Cardiol. 2017; In Press.

  7. Reddy VY, Doshi SK, Kar S, et al. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. J. Am Coll Cardiol. 2017; In Press.

  8. Reddy VY, Doshi SK, Kar S, et al. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. J. Am Coll Cardiol. 2017; In Press.

  9. Price MJ, Reddy VY, Valderrábano M, et al. Bleeding outcomes after left atrial appendage closure compared with long-term warfarin: a pooled, patient-level analysis of the WATCHMAN randomized trial experience. JACC Cardiovasc Interv.2015;8(15):1925-1932.

  10. Reddy VY, Gibson DN, Kar S, et al. Post-FDA approval, initial US clinical experience with Watchman Left Atrial Appendage Closure for stroke prevention in atrial fibrillation. J Am Coll Cardiol. doi: 10.1016/j.jacc.2016.10.010.

  11. Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1-12.

  12. Boersma LV, Schmidt B, Betts TR, et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. European Heart Journal. 2016; pii:ehv730.

  13. WATCHMAN Left Atrial Appendage Closure (LAAC) Technology for Patients with Non-Valvular Atrial Fibrillation. Sponsor’s Executive Summary. FDA Circulatory Systems Devices Panel Meeting. October 8, 2014. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/UCM417177.pdf. Accessed September 10, 2016.

  14. Cappato R, Calkins H, Chen SA, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3:32-38.

  15. Deshmukh A, Patel NJ, Pant S, et al. In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93,801 procedures. Circulation. 2013;128:2104-2112.

  16. WATCHMAN FDA Panel Sponsor Presentation. Oct 2014;

  17. Boersma, L.et al. EHJ; published online Jan 2016 in press

  18. Boersma, L.et al. EHJ; published online Jan 2016 in press;

  19. Reddy VY, Holmes DR, et al. JACC 2016; Article in press

  20. Reddy, VY et al. Circulation. 2011;123:417-424.

  21. Holmes, DR et al. JACC 2014; 64(1):1-12.

  22. Aonuma K, et al. Circ J. Advance Publication on June 26, 2020. doi: 10.1253/circj.CJ-20-0196.

  23. Blackshear J. and Odell J., Annals of Thoracic Surgery. 1996; 61: 755-759.

  24. Circulation. 2021 May　4;143(18):1754-1762